CLAIMS

1. A pharmaceutical composition comprising, β-endorphin and adrenocorticotropic hormone (ACTH) or analogues thereof of either or both.

2. A pharmaceutical composition comprising, two active agents, wherein the active agents consist of β-endorphin and ACTH or analogues thereof.

3. The pharmaceutical composition of claim 1, which does not comprise any pro-opiomelanocortin (POMC)-derived peptides other than β-endorphin and ACTH.

4. A repository formulation comprising the pharmaceutical composition of any one of claims 1 to 3.

5. The repository formulation of claim 4 comprising gelatin.

6. The repository formulation of claim 5 comprising 15-17% gelatin.

7. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the β-endorphin has the sequence of human β-endorphin (SEQ ID NO: 1).

8. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the β-endorphin has the sequence of bovine β-endorphin (SEQ ID NO: 3).

9. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the β-endorphin has the sequence of porcine β-endorphin (SEQ ID NO: 5).

10. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the ACTH has the sequence of human ACTH (SEQ ID NO: 2).

11. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the ACTH has the sequence of bovine ACTH (SEQ ID NO: 4).

12. The composition of any one of claims 1-2, or the formulation of any one of claims 4-6, wherein the ACTH has the sequence of porcine ACTH (SEQ ID NO: 6 or SEQ ID NO: 7).

13. The pharmaceutical composition or formulation of any one of claims 1 to 12 for use in therapy.

14. Use of the pharmaceutical composition or formulation of any one of claims 1 to 12 in the preparation of a medicament for the treatment of an inflammatory, autoimmune, allergic, or neurologic disease or disorder, wherein the medicament is to be administered.

15. The use of claim 14, wherein the neurologic disorder is infantile spasm, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, or electrical status epilepticus in sleep.

16. The use of claim 14, wherein the inflammatory or autoimmune disease is multiple sclerosis.

17. The use of claim 14, wherein the inflammatory or autoimmune disease is psoriatic arthritis; rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus or systemic dermatomyositis.

18. The use of claim 14, wherein the inflammatory or allergic disorder is an ophthalmic disease.

19. The use of claim 18, wherein the ophthalmic disease is keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, or anterior segment inflammation.

20. The use of claim 14, wherein the inflammatory or allergic disorder is edema, severe erythema multiforme, Stevens-Johnson syndrome, serum sickness, or symptomatic sarcoidosis.

21. The use of any one of claims 14-20, wherein Tempol is to be further administered.

22. A syringe, pre-filled with the formulation of any one of claims 4 to 12.

23. The use of the composition of any one of claims 1-2, or the formulation of any one of claims 4-6, in the preparation of a medicament for the treatment an inflammatory, autoimmune, allergic, or neurologic disease or disorder.